Table: Sapporo Clinical Lab -2016/17 parent results
May 12 (Reuters)-
Sapporo Clinical Laboratory Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2017 Mar 31, 2016 Mar 31, 2018 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 15.87 16.27 16.29 8.09
(-2.5 pct) (+3.4 pct) (+2.7 pct) (+2.9 pct)
Operating 734 mln 933 mln
(-21.3 pct) (+11.9 pct)
Recurring 764 mln 961 mln 726 mln 337 mln
(-20.4 pct) (+11.0 pct) (-5.0 pct) (-4.4 pct)
Net 488 mln 569 mln 490 mln 227 mln
(-14.3 pct) (+1.9 pct) (+0.5 pct) (-0.8 pct)
EPS 140.39 yen 163.80 yen 141.10 yen 65.48 yen
Ann Div 10.00 yen 11.00 yen 10.00 yen
-Q2 Div NIL NIL NIL
-Q4 Div 10.00 yen 11.00 yen 10.00 yen
NOTE - Sapporo Clinical Laboratory Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=9776.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Sapporo Clinical Laboratory
See all newsTable: Sapporo Clinical Lab - 9-MTH group results
Table: Sapporo Clinical Lab - 6-MTH group results
Brief: Sapporo Clinical Laboratory Inc - To Retire Treasury Shares Worth 26% Of Outstanding Stock On Feb 17
Table: Sapporo Clinical Lab -Q1 group results
Table: Sapporo Clinical Lab -2024/25 parent results